Use of Sitagliptin to Decrease Microalbuminuria
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 142 participants.
Also called NCT02048904
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 142 participants
- Sponsor
- University of Missouri-Columbia
- Registry
-
NCT02048904
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT02048904. Randomized; double masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2017-08-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Use of Sitagliptin to Decrease Microalbuminuria
- Condition
- Type 2 Diabetes
- Condition
- Microalbuminuria
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Missouri-Columbia
Record details
- Record id
cardio:ct-nct02048904- Content hash
c455362e8bfa5e9c5489e463bc77fae9554355578d07e2c86928d0ffc0340724